RegCell appoints to new CEO

Osaka, Japan-based biotech RegCell today announced the appointment of experienced life science exec Michael McCullar, as its new president, chief executive and representative director.

RegCell, which was co-founded by Prof Shimon Sakaguchi, a distinguished Professor at Osaka University and  Kyoto University in 1995, is developing novel therapies for autoimmune diseases by leveraging the natural biology of regulatory T cells (Tregs) with its next-generation cell reprogramming platform.

Dr McCullar has a wealth of experience in the biotech and pharmaceutical industries, spanning more than two decades. Throughout his career, he has been involved in various aspects of drug development and played pivotal roles in the success of several pharmaceutical companies. Dr McCullar formerly served as the CEO of OnQuality Pharmaceuticals, where he provided executive leadership to this targeted oncology supportive therapy company focused on developing pioneering medications tailored to address the intricacies of cancer treatment-related toxicities. Before that, he was chief operating officer at Tolero Pharmaceuticals, where he had a prominent role in the company's acquisition by Sumitomo Dainippon Pharma.